Across these ethical considerations, the researchers emphasize the importance of collaborating with patients and their caregivers.
Amidst a changing landscape for spinal muscular atrophy (SMA), researchers from Australia have outlined ethical considerations stakeholders face when it comes to both the screening and treatment of the disease, including how severity of disease is taken into account.
Across these ethical considerations, the researchers emphasized the importance of collaborating with patients and their caregivers, including in decisions about treatment eligibility as additional longitudinal evidence becomes available for treatments like risdiplam (approved in 2020) and nusinersen (approved in 2016), both of which have shown improvements in motor function and survival.
“While new therapies for SMA are extremely welcome, the rapid pace of their development is generating ethical complexity for health professionals and families. The long-term effects and outcomes of novel therapies for SMA remain uncertain,” the study authors wrote in Australian Journal of General Practice. “While they may prevent further decline, disease-modifying therapies are not a cure for SMA, and children who commence treatment after symptom onset might continue to live with impairment. It is important to manage parental optimism and hope, and ensure that benefits are not overestimated while possible harms are underplayed.”
Access to these treatments also poses concerns, explained the researchers, citing restrictions related to age, treatment location, SMN2 copies, and disease progression. For example, patients who are presymptomatic with at least 3 copies of SMN2 are unable to be reimbursed for disease-modifying treatments.
In their paper, the researchers also pose ethical considerations for SMA prior to and immediately after birth. As with other genetic conditions, SMA is included in most commercial panels for reproductive carrier screening (RCS). If it’s determined that a child will likely have SMA, parents have the option for further interventions, including undergoing preimplantation genetic testing where they choose an embryo without 2 copies of the SMN1 pathogenic variant.
Prenatal diagnosis is also used to help a couple prepare for or avoid the birth of a child with SMA.
The researchers noted that although RCS gives parents the opportunity to make their own reproductive decisions, the process also carries ethical concerns, with the group recommending couples be referred to appropriate RCS providers who are available to provide counseling after testing.
“For SMA specifically, identifying carriers of a pathogenic variant in the SMN1 gene does not, on its own, predict the severity of SMA that a child may develop,” they explained. “A further consideration is the wider debate on the place of disability and difference in society. It has been argued that prenatal screening is unjustly discriminatory, particularly when there is variable presentation. Reasons include an implicit purpose of eradicating disability and diminishing diversity, thereby devaluing people living with genetic conditions such as SMA.”
With an emphasis placed on timely intervention, newborn screening (NBS) is recognized as another crucial opportunity for early detection of the disease, with countries worldwide implementing NBS programs.
However, similar to RCS, the screening method also comes with controversies, as in the case of a patient having more than 3 copies of SMN2, leaving questions of the severity of disease and uncertainty around when the patient will present with symptoms and how and when should intervention be initiated.
Reference
Newson AJ, Dive L, Cini J, Hurley E, Farrar MA. Ethical aspects of the changing landscape for spinal muscular atrophy management in Australia. Aust J Gen Pract. 2022;51(3):131-135. doi:10.31128/AJGP-06-21-6028
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More